| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.006 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.091 | 0.008 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |